Intervacc (IVACC) Stora Aktiedagarna 2026 summary

Business overview and technology

• Focus on animal health vaccines using a unique recombinant fusion protein platform, targeting horses and pigs.

• Lead product Strangvac targets strangles in horses, with Piggyvac in development for piglets.

• Strangvac offers strong immunogenicity, safety, and stability, with a differentiated immune response for tracking infection.

• The company maintains a profitable business in Scandinavia, selling both in-house vaccines and complementary veterinary products.

• Listed on First North with a market cap over SEK 200 million and SEK 160 million in cash at year-end.

Market opportunity and product performance

• Strangles is a highly contagious and economically impactful equine disease, with up to 10% mortality.

• Primary markets include Europe, USA, Australia, and New Zealand, with 30–70% of horse owners vaccinating regularly.

• Estimated annual market potential is 11 million doses in primary regions.

• Field studies show up to 94% protection, with low adverse event rates and cross-protection against other pathogens.

• Sales of Strangvac increased by 300% in Europe last year, from a low base.

Commercial strategy and expansion plans

• Initial launches in Sweden, Denmark, and UK, with active expansion planned for France and Germany.

• Key opinion leaders drive adoption through studies, guidelines, and recommendations.

• US regulatory process ongoing, with safety and efficacy studies extending into 2027; commercial launch expected after that.

• Plans to partner with major US vaccine companies for market entry.

• Production capacity is robust, with no current bottlenecks anticipated.